Bharat Biotech's Intranasal Covid Vaccine To Be Available On Cowin App From Today
HY News
23 December, 2022 02:12 pm IST
Text Size:
Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above and is likely to be introduced on the Co-WIN platform this evening.
Newsagency PTI reported that the needle-free vaccine will be available at private hospitals as of now. It is likely to be rolled out in the national Covid vaccination programme soon.
The nasal vaccine -- BBV154 --had received approval of the Drugs Controller General of India (DCGI) in November for restricted use in an emergency situation for those above 18 years as a heterologous booster dose.
"The vaccine branded as iNCOVACC is likely to be introduced on the Co-WIN platform Friday evening onwards. For now it will be available in private hospitals," an official source said.
iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results, the Hyderabad-based vaccine-maker had said in a statement.
The nasal vaccine BBV154 had received approval of the Drugs Controller General of India in November for restricted use in an emergency situation for those above 18 as a heterologous booster dose.
The approval for the vaccine comes amid a spurt in Covid cases in China and some other countries around the world.
Subscribe to our mailing list to get the new updates!
Subscribe our newsletter to stay updated
Leave Comments